Cargando…
PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines
Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and als...
Autores principales: | Ginés, Alba, Bystrup, Sara, Ruiz de Porras, Vicenç, Guardia, Cristina, Musulén, Eva, Martínez-Cardús, Anna, Manzano, José Luis, Layos, Laura, Abad, Albert, Martínez-Balibrea, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425499/ https://www.ncbi.nlm.nih.gov/pubmed/25955657 http://dx.doi.org/10.1371/journal.pone.0123830 |
Ejemplares similares
-
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2016) -
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2019) -
Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?
por: Layos, Laura, et al.
Publicado: (2022) -
Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
por: Moutinho, Catia, et al.
Publicado: (2013) -
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
por: Bernat-Peguera, Adrià, et al.
Publicado: (2022)